SCHEMBL22313787

SCHEMBL22313787

CCc1ccc(-c2ccnc(OC)c2)cc1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 1/20 0.45
ACVR2A P27037 2/20 0.43
TGFBR2 P37173 2/20 0.43
TGFBR1 P36897 1/20 0.43
CNR1 P21554 1/20 0.41
S1PR1 P21453 1/20 0.41
LOX P28300 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
AAK1 Q2M2I8 5/20 0.41
NR4A2 P43354 1/20 0.40
DHODH Q02127 1/20 0.40
FEN1 P39748 1/20 0.40
CHRNA7 P36544 1/20 0.39
LRRK2 Q5S007 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
MAPT P10636 2/20 0.39
WNT3A P56704 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22313714 0.81 GABRG2 (0.49)
SCHEMBL22797385 0.80 S1PR1 (0.49) SLC13A5ACVR2ATGFBR2TGFBR1CNR1
SCHEMBL22313789 0.79 PDK1 (0.42) CYP3A4
SCHEMBL17493530 0.78 NR4A2 (0.47) SLC13A5NR4A2DHODHMAPK13MAPK12
SCHEMBL30626327 0.78 LOX (0.55) SLC13A5ACVR2ATGFBR2TGFBR1CNR1
SCHEMBL16116782 0.78 LOX (0.55) SLC13A5ACVR2ATGFBR2TGFBR1CNR1
SCHEMBL16528083 0.78 HSD17B1 (0.50) MAPTCYP3A4
SCHEMBL22313751 0.77 AAK1 (0.43) SLC13A5CNR1S1PR1LOXLOXL2
SCHEMBL22283952 0.77 HSD17B1 (0.49) SLC13A5CNR1S1PR1LOXLOXL2
SCHEMBL23249814 0.76 CNR1 (0.50) SLC13A5CNR1S1PR1LOXLOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230025130-A1 METHODS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-11162101-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-11-02 US disclosed
US-11129829-B2 Methods for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-09-28 US disclosed
US-20200390765-A1 METHODS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-12-17 US disclosed
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11129829-B2 Methods for modulating splicing RBM17, SNRPE, SNRPB2 SLC13A5 4302/4885ACVR2A 3147/4885TGFBR2 4572/4885
US-20230025130-A1 METHODS FOR MODULATING SPLICING RBM17, SNRPE, SNRPB2 SLC13A5 4302/4885ACVR2A 3147/4885TGFBR2 4572/4885
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 SLC13A5 4640/4885ACVR2A 3244/4885TGFBR2 4610/4885
US-11162101-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 SLC13A5 4640/4885ACVR2A 3244/4885TGFBR2 4610/4885
US-20200390765-A1 METHODS FOR MODULATING SPLICING RBM17, SNRPE, SNRPB2 SLC13A5 4302/4885ACVR2A 3147/4885TGFBR2 4572/4885
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 SLC13A5 4640/4885ACVR2A 3244/4885TGFBR2 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.